Conferences

A 13-year study of type 2 diabetes patients has found metformin, one of the world’s highest-grossing anti-diabetic medications, could be protective against age-related macular degeneration, a leading cause of blindness in Americans older than 50.

With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.

Evolocumab appears to be equally effective at reducing LDL cholesterol and preventing cardiovascular events regardless of a patient’s kidney function, according to a new subanalysis of the FOURIER outcomes study presented at the American Society of Nephrology’s annual Kidney Week in San Diego.

Canadian physicians are calling for nationwide CVD screening for all competitive high school athletes, CTV News reported this week of new guidelines issued at the Canadian Cardiovascular Congress in Toronto.

Patients with heart disease should aim to be physically active seven minutes for every 20 they’re sedentary to prolong life and prevent further cardiovascular damage, according to research presented at the 2018 Canadian Cardiovascular Congress in Toronto.

A study presented at TCT 2018 questioned the benefits of “drip-and-ship” for elderly patients with ST-segment elevation myocardial infarction (STEMI), finding patients in their 80s or older who were transferred with fibrinolytic therapy for PCI had an eight-fold risk of hemorrhagic stroke but no survival advantage.

Fewer than one-third of Chinese patients with acute coronary syndromes (ACS) receive guidance to participate in cardiac rehabilitation, according to research presented Oct. 11 at the Great Wall International Congress of Cardiology.

Lorcaserin, an appetite suppressant approved for chronic weight management in 2012, reduced overweight patients’ risk for developing type 2 diabetes (T2D) and improved remission of hyperglycemia in a study of more than 12,000 Massachusetts residents, researchers reported.

With CMS set to release a new National Coverage Determination (NCD) for transcatheter aortic valve replacement (TAVR) next June, researchers at TCT 2018 weighed in on what the new procedural volume thresholds should look like.

Some cardiologists at TCT 2018 worried negative posts about ongoing trials could affect patient enrollment, while others encouraged more colleagues to join social media discussions so the medical community can better quash misinformation.

A press conference at the 2018 Transcatheter Cardiovascular Therapeutics meeting in San Diego on Tuesday, Sept. 25, morphed into a discussion about the future of bioresorbable vascular scaffolds (BVS) and whether it’s worth pursuing bioresorbable stent technology at all.

Acute coronary syndrome patients who were given a loading dose of atorvastatin before percutaneous coronary intervention (PCI) experienced a 28 percent reduction in major adverse cardiovascular events (MACE) over the following 30 days, according to a secondary analysis of the randomized SECURE-PCI trial published in JAMA Cardiology.